Journal
CHEMICAL ENGINEERING JOURNAL
Volume 451, Issue -, Pages -Publisher
ELSEVIER SCIENCE SA
DOI: 10.1016/j.cej.2022.138971
Keywords
Tumor-associated macrophages; Doxil; Macrophage-derived microparticles; Chemoimmunotherapy; Antitumor immune memory
Categories
Ask authors/readers for more resources
Mannose-engineered macrophage-derived microparticles can efficiently repolarize M2-like TAMs enriched with Doxil, improving the immunotherapy and increasing tumor accumulation and penetration of Doxil.
Insufficient tumor accumulation and distribution, as well as low antitumor immunity and enriched M2-like tumor-associated macrophages (TAMs) severely limit the therapeutic efficacy of liposomal doxorubicin (Doxil). Here, mannose-engineered macrophage-derived microparticles loading metformin (Met@Man-MPs) efficiently repolarize Doxil-enriched M2-like TAMs to M1-like phenotype. Doxil elicits immunogenic cell death (ICD) of tumor cells and activates STING pathway to facilitate the phagocytosis of tumor cells by Met@Man-MPs-repolarized M2-like TAMs, contributing to macrophage maturation and CD8(+) T cell activation. In addition, Met@Man-MPs efficiently increase the tumor accumulation and penetration of Doxil. Thus, combination treatment of Met@Man-MPs and Doxil generates strong anticancer activity and long-term antitumor immune memory against tumor recurrence. Our results demonstrate that Met@Man-MPs are the potential candidates to improve Doxil chemoimmunotherapy in cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available